Literature DB >> 11846459

Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery.

Gennaro Galizia1, Michele Orditura, Ciro Romano, Eva Lieto, Paolo Castellano, Luigi Pelosio, Vincenzo Imperatore, Giuseppe Catalano, Carlo Pignatelli, Ferdinando De Vita.   

Abstract

The prognostic significance of IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery was investigated. To this end, 50 candidate patients with colon cancer for surgery were admitted to the study. Of these, 30 could be subjected to a potentially curative surgery. Cytokine serum levels at several time points before and after surgery were measured by ELISA. Circulating levels of IL-10 and IL-6 were found to be elevated in cancer patients with respect to controls. Both IL-10 and IL-6 serum levels were demonstrated to predict the likelihood of curative surgery (predictive accuracy, 83.3%). IL-10 serum levels returned to normal in all but 6 patients who underwent curative surgery. These latter had tumor recurrence (predictive accuracy, 100%). In contrast, IL-6 serum levels significantly decreased in all patients, regardless of whether cure was surgically achieved, but did not normalize. On multivariate analysis, basal IL-10 serum levels were found to be among the variables significantly predicting the disease-free survival rate. Stepwise regression selected tumor stage, basal IL-10 serum level, and basal CEA serum level as the best combination of variables for prediction of the likelihood of tumor recurrence. In conclusion, preoperative serum levels of IL-10 were shown to be useful markers for predicting both likelihood to perform curative surgery and, in combination with the 16th postoperative day IL-10 serum levels, tumor recurrence (predictive accuracy, 73.6 and 96%, respectively). IL-6 serum levels were found to have a more limited prognostic role. Copyright 2001 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11846459     DOI: 10.1006/clim.2001.5163

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  63 in total

Review 1.  Dual roles for immunity in gastrointestinal cancers.

Authors:  Cristina Ferrone; Glenn Dranoff
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 2.  Immune cell interplay in colorectal cancer prognosis.

Authors:  Samuel E Norton; Kirsten A Ward-Hartstonge; Edward S Taylor; Roslyn A Kemp
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

3.  Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer.

Authors:  Sonja Badovinac; Marta Korsic; Davorka Mursic; Miroslav Samarzija; Branka Cucevic; Mihovil Roglic; Marko Jakopovic
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  Disseminated Kaposi's sarcoma in patients with HIV infection correlates to high serum levels of IL-10.

Authors:  Paula Renata Lima Machado; Kleber Juvenal Silva Farias; Julieta Genre; Carlo José Freire Oliveira; Paulo Marcos Matta Guedes; Benedito Antônio Lopes da Fonseca
Journal:  Viral Immunol       Date:  2014-07-15       Impact factor: 2.257

5.  Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients.

Authors:  E-M Reitter; C Ay; A Kaider; R Pirker; C Zielinski; G Zlabinger; I Pabinger
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

6.  Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.

Authors:  Kyung A Kwon; Sung Hyun Kim; Sung Yong Oh; Suee Lee; Jin-Yeong Han; Kyeong Hee Kim; Ri Young Goh; Hong Jo Choi; Ki Jae Park; Mee Sook Roh; Hyo-Jin Kim; Hyuk-Chan Kwon; Jong Hoon Lee
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

7.  Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial.

Authors:  G Bobe; G Murphy; P S Albert; L B Sansbury; E Lanza; A Schatzkin; N H Colburn; A J Cross
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

8.  Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer.

Authors:  Emily L Lowe; Timothy R Crother; Shervin Rabizadeh; Bing Hu; Hanlin Wang; Shuang Chen; Kenichi Shimada; Michelle H Wong; Kathrin S Michelsen; Moshe Arditi
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

9.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.

Authors:  Y Okugawa; C Miki; Y Toiyama; H Yasuda; T Yokoe; S Saigusa; J Hiro; K Tanaka; Y Inoue; M Kusunoki
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

Review 10.  Colitis-associated cancer: the role of T cells in tumor development.

Authors:  Maximilian J Waldner; Markus F Neurath
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.